Ocean Biomedical, Inc. (OCEA) Stock Price & Analysis
Ocean Biomedical, Inc. (OCEA) rose 0.00% to USD 0 as of June 10, 2026 at 09:02 UTC, according to Nexqual real-time market data.
OCEA last closed at USD 0; the session ranged USD 0–0 on volume of 7,780 shares. Market capitalization is $46,473, with a 52-week range of USD 0–0.02 (PNK). Source: Nexqual, June 10, 2026 at 09:02 UTC.
Key Statistics (as of June 10, 2026 at 09:02 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.02 |
| Volume | 7,780 shares |
| Market Cap | $46,473 |
| Exchange | PNK |
Technical Analysis (OCEA)
Nexqual's technical model rates OCEA "STRONG SELL" based on 0 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 09:02 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 52.74 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (OCEA)
Wall Street analysts rate OCEA "None", per Nexqual as of June 10, 2026 at 09:02 UTC.
| Consensus Rating | None |
|---|
Earnings (OCEA)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-06-30 | USD -0.41 vs est -0.2 ▼ miss |
| 2023-03-31 | USD -0.27 vs est -0.17 ▼ miss |
Source: Nexqual, June 10, 2026 at 09:02 UTC.
Financials & Fundamentals (OCEA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.06 |
| Total Debt | $15.35M |
| Free Cash Flow | $-5.34M |
Source: Nexqual, June 10, 2026 at 09:02 UTC.
Financial Health Score (OCEA)
Nexqual rates Ocean Biomedical, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 09:02 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — No data |
| Cash Flow | Weak — Operating cash flow -$4M |
| Efficiency | Mixed — No data |
Ownership (OCEA)
| Insider Ownership | +10.31% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 232.37M |
| Float | 208.41M |
| Short % of Float | +2.05% |
Source: Nexqual, June 10, 2026 at 09:02 UTC.
Leadership (OCEA)
Ocean Biomedical, Inc. is led by Inderjote Kathuria (age 57), Chief Strategy Officer, per Nexqual as of June 10, 2026 at 09:02 UTC.
| Chief Strategy Officer | Inderjote Kathuria (age 57) |
|---|---|
| Founder & Executive Chairman of the Board | Chirinjeev Baboo Kathuria (age 59) |
Major Backers & Investors (OCEA)
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.17% |
Source: Nexqual, June 10, 2026 at 09:02 UTC.
From Ocean Biomedical, Inc.'s Latest SEC 10-K Filing (filed 2025-04-08)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe that our differentiated business model positions us to capture inventions created at these institutions that might otherwise fail to be commercialized to benefit patients.
- We are organized around a licensing and subsidiary structure that we believe will enable us to create mutual value for us and potential licensing partners.
- We believe this structure, combined with the networks of our leadership team, allows us to opportunistically build a continuous pipeline of promising product innovations through our existing and potential future relationships with research institutions.
- We believe the WPDS platform may enable us to discover new targets for other infectious diseases in the future.
Partnerships
- Our criteria are listed below, and we score and weigh each criterion through a combination of data analytics, experience and judgment.         Step Two: Executing License Agreements   After a new program is selected via the process outlined above, or in some cases as part of the selection process, we endeavor to negotiate and execute a license agreement with the relevant university or medical center.
- Under normal circumstances, immune responses are activated to deal with pathogens and non-self antigens but are then inhibited to prevent overexuberant, injury-inducing, immune responses.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. | USD 0.17 | ▼ 12.55% |
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.94 | ▼ 1.02% |
| LYTHF | Lytus Technologies Holdings PTV | USD 11.7 | ▲ 0% |
| ACON | Aclarion, Inc. | USD 3.26 | ▼ 8.68% |
| CXAI | CXApp Inc. | USD 0.22 | ▼ 9.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:02 UTC. This page is informational and not investment advice.